This review explores chondrosarcoma subtypes, diagnostic approaches, prognostic factors, and molecular alterations, followed by a discussion of current and emerging treatment strategies. Emphasis is placed on clinical trials investigating targeted therapies or immunotherapies for advanced chondrosarcoma, including inhibitors of IDH1/2 and multiple kinases, death receptor 5 agonism, and other potential new therapeutic approaches.

1 day ago

Review • Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • TNFRSF10B (TNF Receptor Superfamily Member 10b)

PD-L1 expression • TP53 mutation

Gain of function p53 mutant R273H confers distinct methylation profiles and consequent YAP/TAZ signaling mediated activation of partial or full EMT states to colon tumours. (PubMed, Epigenetics Chromatin)

We identified a distinct epigenetic signature associated with the p53 R273H mutation, characterised by hypomethylation of YAP/TAZ signalling genes that drives partial EMT and aggressive tumour behaviour. These findings highlight the importance of mutation-specific epigenetic regulation in shaping colorectal cancer progression and the need for developing therapeutic strategies tailored to p53 mutation status.

2 days ago

Journal • P53mut

TP53 (Tumor protein P53)

TP53 mutation

Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p Deletion. (PubMed, Am J Hematol)

Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p Deletion.

3 days ago

Journal • Real-world evidence

TP53 (Tumor protein P53)

TP53 mutation

AND logic-gated CRISPR/Cas9 and hybridization chain reaction system for precise ctDNA detection. (PubMed, J Nanobiotechnology)

Furthermore, we validated the specificity of our approach by successfully detecting various mutations, including KRAS G12C, KRAS G12D, EGFR T790M and TP53 R273H, in simulated clinical samples. These findings highlight a reliable method for precise ctDNA detection, offering high specificity, selectivity, and accuracy, thus paving the way for potential cancer diagnostic application.

3 days ago

Journal • Circulating tumor DNA

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)

TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • EGFR T790M • KRAS G12D • KRAS G12

Thyroid-originated pleomorphic rhabdomyosarcoma with novel TP 53 intron frameshift mutation: a case report and literature review. (PubMed, World J Surg Oncol)

Under specific circumstances, CNB can provide an effective diagnostic approach for thyroid tumors. Moreover, in this case, we identified a novel TP53 intronic mutation that may drive the development of thyroid PRMS.

3 days ago

Journal

BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NKX2-1 (NK2 Homeobox 1) • MYOD1 (Myogenic Differentiation 1)

TP53 mutation • BRAF V600E • BRAF V600 • RET mutation • RET rearrangement

Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors. (PubMed, NPJ Breast Cancer)

Consistently, supplementing primary HER2-positive tumor cultures with recombinant SAA1, SAA2, or THBS4 peptides enhanced tumor cell proliferation and migration. Together, these findings uncover a mechanism by which fibroblastic mutant p53 promotes mammary tumorigenesis-through upregulating secretory proteins such as SAA1, SAA2, and THBS4 in the stroma, thereby enhancing PI3K/AKT signaling and tumor progression.

3 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • SAA1 (Serum Amyloid A1) • SAA2 (Serum Amyloid A2)

HER-2 positive • TP53 mutation • TP53 wild-type

Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer. (PubMed, J Genet Eng Biotechnol)

Our findings underscore the prognostic value of the identified genes and the immunosuppressive TME in TP53-mutant breast cancer. The identification of drug candidates with strong binding affinities to key proteins provides promising avenues for targeted therapy in this high-risk patient population.

3 days ago

Journal

ER (Estrogen receptor) • TP53 (Tumor protein P53) • FGFR4 (Fibroblast growth factor receptor 4) • CA9 (Carbonic anhydrase 9) • AGR3 (Anterior Gradient 3, Protein Disulphide Isomerase Family Member) • TFF1 (Trefoil Factor 1) • S100P (S100 calcium binding protein P)

TP53 mutation

Mekinist (trametinib) • docetaxel • lapatinib

Identifying actionable genetic mutations and microsatellite instability in liquid biopsy of colorectal cancer. (PubMed, J Genet Eng Biotechnol)

CRC genetic mutational statuses as well as contributing environmental stress factors such as gut microbiota dysbiosis are prognostically crucial, associated with high risk potential of gene-environment interactions based on machine learning.

3 days ago

Journal • Liquid biopsy • Microsatellite instability

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • FGFR3 (Fibroblast growth factor receptor 3) • KDR (Kinase insert domain receptor)

TP53 mutation • PIK3CA mutation

5-fluorouracil • capecitabine • leucovorin calcium

Transcriptome profiling by RNA sequencing reveals novel targets of Gemini nano curcumin on p53-mutant HT-29 colorectal cancer cells. (PubMed, J Genet Eng Biotechnol)

Our data reveal that nanocurcumin might affects HT-29 colorectal cancer cells through modulating different pathways such as endoplasmic reticulum response, and transporter-related genes. More studies necessitate to unravel the molecular mechanisms and proteins involved in these pathways that could be considered as novel therapeutic targets in colorectal cancer.

3 days ago

Journal • P53mut

TP53 (Tumor protein P53)

TP53 mutation

Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis. (PubMed, Br J Haematol)

This work provides the first genomic characterisation of a diagnosed MDS cohort in China and establishes the first risk prediction model for MDS-to-AML transformation, alongside novel prognostic models for OS and PFS. These tools offer improved prognostic prediction and potential guidance for therapeutic strategies in Chinese patients with MDS.

3 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • ETV6 (ETS Variant Transcription Factor 6) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • CSF3R (Colony Stimulating Factor 3 Receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2) • GATA2 (GATA Binding Protein 2) • CALR (Calreticulin)

TP53 mutation • SRSF2 mutation • STAT3 mutation

E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study. (PubMed, ESMO Open)

In heavily pretreated patients with advanced solid tumors, E7386 demonstrated a manageable safety profile and a dose-dependent PK profile. PRs were noted in patients with small bowel carcinoma or desmoid tumor.

3 days ago

P1 data • Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • APC (APC Regulator Of WNT Signaling Pathway)

TP53 mutation • KRAS mutation

E7386

Surgical stage in the era of molecular profiling of endometrial cancer. (PubMed, Eur J Cancer)

Surgical stage remains a strong prognostic factor across molecular subtypes and should be considered alongside molecular classification when tailoring adjuvant treatment in EC.

3 days ago

Journal

TP53 (Tumor protein P53) • POLE (DNA Polymerase Epsilon)

TP53 mutation • MSI-H/dMMR • POLE mutation